@article{28124cbc9108425eb94a45d74c03ac24,
title = "The multidisciplinary management of cholangiocarcinoma",
abstract = "Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver-directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.",
keywords = "biliary disease, cholangiocarcinoma, multidisciplinary, primary liver malignancy, radiotherapy",
author = "Ohaegbulam, {Kim C.} and Yilun Koethe and Alice Fung and Mayo, {Skye C.} and Grossberg, {Aaron J.} and Chen, {Emerson Y.} and Kaveh Sharzehi and Adel Kardosh and Khashayar Farsad and Rocha, {Flavio G.} and Thomas, {Charles R.} and Nima Nabavizadeh",
note = "Funding Information: Charles R. Thomas reports consulting fees from the American Medical Association. Khashayar Farsad reports consulting fees from Eisai Co., Ltd, Genentech; Guerbet LLC, and NeuWave Medical, Inc. Alice Fung reports consulting fees from Elsevier and the Oregon Gut Club and travel fees from Oregon Health and Science University. Aaron J. Grossberg reports consulting fees from Endevica Bio. Yilun Koethe reports consulting fees from AngioDynamics, Inc, Cook Medical, CrannMed, and Johnson & Johnson Health Care Systems Inc. Skye C. Mayo reports independent contracting fees from Amplity Health Lynx Group. Flavio G. Rocha reports independent contracting fees from AstraZeneca and consulting fees from Medtronic. Nima Nabavizadeh reports grant funding from Illumina. The other authors made no disclosures. Publisher Copyright: {\textcopyright} 2022 American Cancer Society.",
year = "2023",
month = jan,
day = "15",
doi = "10.1002/cncr.34541",
language = "English (US)",
volume = "129",
pages = "184--214",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",
}